ALI, Yesuf Elias, Abanoub RIAD, Ahmad SOFI-MAHMUDI, Sudhakar MORANKAR, Mekonnen ADDISALEM, Endalkachew SELAMAWIT, Mama FEYISSA, Muhidin SEMIRA, Ayele BETHELHEM, Yahya MOHAMMED, Usman ABDUSELAM, Abafita JEMAL a Miloslav KLUGAR. Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study. Frontiers in Public Health. LAUSANNE: FRONTIERS MEDIA SA, 2022, roč. 10, July 2022, s. 1-10. ISSN 2296-2565. Dostupné z: https://dx.doi.org/10.3389/fpubh.2022.937794.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study
Autoři ALI, Yesuf Elias, Abanoub RIAD (818 Egypt, garant, domácí), Ahmad SOFI-MAHMUDI, Sudhakar MORANKAR, Mekonnen ADDISALEM, Endalkachew SELAMAWIT, Mama FEYISSA, Muhidin SEMIRA, Ayele BETHELHEM, Yahya MOHAMMED, Usman ABDUSELAM, Abafita JEMAL a Miloslav KLUGAR (203 Česká republika, domácí).
Vydání Frontiers in Public Health, LAUSANNE, FRONTIERS MEDIA SA, 2022, 2296-2565.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30304 Public and environmental health
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 5.200
Kód RIV RIV/00216224:14110/22:00126336
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3389/fpubh.2022.937794
UT WoS 000835095000001
Klíčová slova anglicky Healthcare workers; COVID-19 vaccine; side effects; Oxford AstraZeneca; Ethiopia; Africa
Štítky 14110525, 14119612, 14119613, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 5. 4. 2023 08:17.
Anotace
Introduction: Ethiopia is the second most populous country in Africa. Ethiopia received most of its COVID-19 vaccines through donations. The Oxford AstraZeneca vaccine is the first to be donated to Ethiopia by the COVAX facility. Healthcare workers were the priority population that received the Oxford AstraZeneca COVID-19 vaccine. However, there was no nationwide study on the safety of the vaccine in Ethiopia. This study aimed to measure the prevalence and predictors of self-reported side effects of the Oxford AstraZeneca vaccine. Materials and methods: The study employed a cross-sectional design. A sample of healthcare workers who took Oxford AstraZeneca COVID-19 vaccine was drawn from four regions of Ethiopia; namely, Amhara, Oromia, Somali, and Southwest. Data were collected on sociodemographic characteristics, medical anamnesis, COVID-19 related anamnesis, and COVID-19 vaccine anamnesis via telephone interview. Descriptive and inferential analyses were done. The software, IBM SPSS Statistics v21.0, was used for analyses of data. Results: Out of 384 people, 346 responded (response rate: 90.1%). Female accounted for 34.1% of the respondents. The mean age of the respondents was 31.0 years (Standard Deviation (SD) = 7.4). Nurses accounted for 43.7% of the respondents. The prevalence of at least one local- and systemic-side effect was 50.6 and 44.5%, respectively. The most frequent local- and systemic- side effect were injection site pain and headache, respectively. Both types of side effects mostly subsided in the first 3 days. A third of healthcare workers with side effects took at least one medication. Paracetamol followed by diclofenac sodium were taken by healthcare workers to overcome side effects. There was no independent predictor of local side effect. After controlling for age and chronic diseases, the odds of healthcare workers with COVID-19 like symptoms to experience systemic side effects was 1.38 (Confidence Interval (CI): 1.04–1.82) times more than that of healthcare workers without COVID-19 like symptoms. Conclusions: The prevalence of local- and systemic-side effects of the Oxford AstraZeneca COVID-19 vaccine was modest. As the symptoms were mostly common in the first 3 days, it is preferable to monitor healthcare workers at least in the first 3 days following the administration of the vaccine.
Návaznosti
EF19_073/0016943, projekt VaVNázev: Interní grantová agentura Masarykovy univerzity
LTC20031, projekt VaVNázev: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST
MUNI/IGA/1104/2021, interní kód MUNázev: COVID-19 Vaccines Safety Tracking in the Czech Republic (Akronym: CoVaST-CZ)
Investor: Masarykova univerzita, COVID-19 Vaccines Safety Tracking in the Czech Republic
VytisknoutZobrazeno: 12. 5. 2024 18:33